Living-donor liver transplantation for moderate or severe porto-pulmonary hypertension accompanied by pulmonary arterial hypertension: a single-centre experience over 2 decades in Japan. by Ogawa, Eri et al.
Title
Living-donor liver transplantation for moderate or severe
porto-pulmonary hypertension accompanied by pulmonary
arterial hypertension: a single-centre experience over 2 decades
in Japan.
Author(s)Ogawa, Eri; Hori, Tomohide; Doi, Hiraku; Segawa, Hajime;Uemoto, Shinji
CitationJournal of hepato-biliary-pancreatic sciences (2012), 19(6):638-649
Issue Date2012-11
URL http://hdl.handle.net/2433/169725




Living-donor liver transplantation for 
moderate or severe porto-pulmonary 
hypertension accompanied by pulmonary 
arterial hypertension: a single-centre 
experience over 2 decades in Japan 
Eri Ogawa1, Tomohide Hori2 , Hiraku Doi3, Hajime Segawa4 and Shinji Uemoto1  
(1) 
Divisions of Hepato-Pancreato-Biliary and Transplant Surgery, Department of 
Surgery, Kyoto University Hospital, 54 Shogoinkawara-cho Sakyo-ku, Kyoto 606-8507, 
Japan 
(2) 
Division of Transplant Surgery, Department of Transplantation, Mayo Clinic in Florida, 
Jacksonville, FL 32224, USA 
(3) 
Division of Pediatric Cardiology, Department of Pediatrics, Kyoto University Hospital, 
Kyoto 606-8507, Japan 
(4) 
Department of Critical Care Medicine and Anesthesia, Kyoto University Hospital, 
Kyoto 606-8507, Japan 
Tomohide Hori (Corresponding author) 
Email: hori.tomohide@mayo.edu 
Shinji Uemoto (Corresponding author) 
Email: uemoto@kyoto-u.ac.jp 
Published online: 16 November 2011 
Abstract 
Background 
Candidates for orthotopic liver transplantation (OLT) often have porto-pulmonary 
hypertension (PPHTN) with pulmonary arterial hypertension (PAH). Poor outcomes of 
PPHTN contraindicate OLT. There are no guidelines for living-donor liver 
transplantation (LDLT) in PPHTN patients. 
Methods 
We present our experiences of LDLT in six patients with moderate or severe PPHTN, 
along with our institutional guidelines. Three had liver cirrhosis and three were 
non-cirrhotic. Catheterization studies were undertaken before, during and after LDLT, 
and the mean pulmonary arterial pressure (mPAP), cardiac output (CO), pulmonary 
vascular resistance and total peripheral resistance (TPR) were monitored. 
Results 
The results showed significant differences in CO and TPR between cirrhotic and 
non-cirrhotic patients before, during and after LDLT. Cirrhotic patients showed 
systemic hyperdynamic state. Two cirrhotic patients showed poor responses to 
pre-transplant treatment, and continued to have increased PAH and poor clinical 
courses after LDLT. LDLT has an advantage of flexible timing of LT. Currently in our 
institution, PPHTN patients with mPAP <40 mmHg are registered for LDLT after 
treatment and catheterization. However, LDLT is performed when mPAP is ≤35 mmHg, 
leading to improved outcomes. 
Conclusion 
PPHTN patients with well-controlled PAH, or secondary PAH resulting from 
porto-systemic shunts, may be appropriate candidates for LDLT after careful 
considerations. 
Keywords 
Living donorLiver transplantationPulmonary arterial hypertensionPorto-pulmonary 
hypertensionLiver cirrhosis 
Abbreviations 
ACR Acute cellular rejection 
AM Abernethy malformation 
AVCT Acute volume challenge test 
BSA Body surface area 
BV Blood volume 
CBA Congenital biliary atresia 
CI Cardiac index 
CO Cardiac output 
DDLT Deceased-donor liver transplantation 
ET-1 Endothelin-1 
GRWR Graft-to-recipient weight ratio 
HPS Hepato-pulmonary syndrome 
ICU Intensive care unit 
LDLT Living-donor liver transplantation 
LNB Liver needle biopsy 
NO Nitric oxide 
OLT Orthotopic liver transplantation 
MELD Model for end-stage liver disease 
mAP Mean arterial pressure 
mPAP Mean pulmonary arterial pressure 
PELD Pediatric end-stage liver disease 
PAH Pulmonary arterial hypertension 
PCWP Pulmonary capillary wedge pressure 
PGI2 Prostaglandin I2 
POD Postoperative day 
PPHTN Porto-pulmonary hypertension 
PVR Pulmonary vascular resistance 
RV Right ventricle 
SPT Steroid pulse therapy 
TPR Total peripheral resistance 
UNOS Uited Network for Organ Sharing 
Introduction 
Advanced liver disease results in cardiopulmonary disorders, including 
porto-pulmonary hypertension (PPHTN) and hepato-pulmonary syndrome (HPS). In 
addition, eventration of the diaphragm because of intractable ascites, or easily broken 
ribs because of vitamin D deficiency, often disrupt ventilation. Hepatic failure and 
pulmonary arterial hypertension (PAH) may also be accompanied by congenital 
diseases such as Alagille syndrome. In immunocompromised patients with end-stage 
liver disease, such problems with the cardiopulmonary circulation result in increased 
mortality. 
Previous studies have shown that (depending on the institutional definition) the 
frequency of cardiopulmonary disorders in patients with liver cirrhosis ranges between 
5.3 and 8.4% [1, 2]. Although PPHTN in patients with advanced liver disease was 
initially defined as PAH because of portal hypertension, the current definition of 
PPHTN includes secondary PAH because of porto-systemic shunts, as seen in 
patients with Abernethy malformation (AM). In other words, the presence of portal 
hypertension may not always be necessary for a diagnosis of PAH [3, 4]. However, 
HPS is defined as liver disease with abnormal pulmonary gas exchange and evidence 
of intrapulmonary vascular dilatation that results in a right-to-left intrapulmonary 
shunt. Therefore, PPHTN and HPS should be considered as different pathological 
states. 
Several studies define the diagnostic criteria for PPHTN in association with portal 
hypertension as follows: (1) mean pulmonary arterial pressure (mPAP) >25 mmHg and 
pulmonary capillary wedge pressure (PCWP) <15 mmHg, (2) pulmonary vascular 
resistance (PVR) >120 dynes s cm−5 and (3) the exclusion of other causes, such as 
congenital cardiac disorders [5–11]. In pediatric patients, an mPAP of >20 mmHg is 
indicative of PPHTN. Previous studies show that 38–41% of PPHTN patients die within 
15 months of diagnosis and that 50% of untreated PPHTN patients die within 6 months 
of diagnosis [3, 12]. PPHTN causes right ventricular dysfunction, and 36% of PPHTN 
patients die during the early postoperative period after orthotopic liver transplantation 
(OLT) because of right ventricular dysfunction, acute respiratory distress syndrome, 
and cardiovascular collapse [13]. This, coupled with poor outcomes after OLT, led 
many physicians to believe that OLT was contraindicated in PPHTN patients with 
moderate (mPAP ≥35 mmHg) or severe (mPAP >50 mmHg) PAH [10, 14, 15]. However, 
some reports suggest that the outcome for OLT in PPHTN patients with mild PAH 
(mPAP <35 mmHg) has improved [13, 16, 17]. Successful OLT in PPHTN patients 
needs to be established, and some studies have focused on this [10, 13, 17–26]. 
However, the actual strategy for OLT in PPHTN patients with PAH is still unclear, 
especially with respect to living-donor liver transplantation (LDLT). 
Though deceased-donor liver transplantations (DDLTs) make up the majority of OLTs 
in the USA and Europe, almost all OLTs performed in Japan are LDLTs. The 
indications for OLT as a treatment for end-stage liver disease are almost identical for 
DDLT and LDLT; however, each OLT has its own particular characteristics. For LDLT, 
donor selection and graft volume are more limited, but shorter cold ischemic times 
and more flexibility in the timing of OLT are an advantage. In this retrospective study, 
we focused on PPHTN patients who underwent LDLT in our institution within the last 
2 decades. To our knowledge, this is the first study of the long-term experiences in a 
single centre performing LDLT in PPHTN patients with PAH. Based on our 
retrospective evaluations, we discuss the outcomes of LDLT in PPHTN patients with 
PAH, with the aim of establishing strategies for the successful use of LDLT as a 
treatment for this condition. 
Patients and methods 
Patients 
A total of 1,421 recipients who underwent LDLT at Kyoto University Hospital between 
1990 and 2010 were enrolled in the study. The median follow-up period was 6.9 years 
[range 1 day (patient died) to 20.5 years]. 
In our institution, all recipients received cardiac survey by Doppler ultrasound 
beforehand. Patients received advanced investigations including catheterization study 
if any abnormalities were detected or suspected. Patients with mild PAH, such as 
those with Alagille syndrome and suspicious cases identified during the survey, 
underwent LDLT without any intensive preoperative therapy for PPHTN. Six patients 
(3 male and 3 female; median age 8.3 years, range 5.0–21.0 years) with moderate or 
severe PAH underwent LDLT. The median body surface area (BSA) was 0.93 m2 
(range 0.67–1.67 m2). The primary disease was congenital biliary atresia (CBA) in four 
cases and AM (one each of type Ib and II) in two cases (Table 1). The two cases of AM 
have been documented in detail elsewhere [27, 28]. The protocol used in this study 
was approved by the Ethics Review Committee for Clinical Studies of Kyoto 
University Graduate School of Medicine (approval no.: E976). 
 
Important parameters for the catheter studies before, during and 
after LDLT 
Cardiac catheter studies were performed before OLT if required. All six patients in 
this study received detailed catheterization studies both before and after LDLT. 
Swan-Ganz catheters were used routinely both during OLT and in the intensive care 
unit (ICU), and cardiac parameters were closely monitored throughout the 
perioperative period. 
mPAP (mmHg), mean arterial pressure (mAP, mmHg), cardiac output (CO, l/min) and 
PCWP (mmHg) values were collected retrospectively. The cardiac index (CI, l/min/m2) 
was calculated as: CO/BSA. The PVR (dynes s cm−5) was calculated using the 
following formula: PVR = (mPAP − PCWP) × 80/CO [13, 17]. Previous studies have 
shown that the total peripheral resistance (TPR) and/or systemic vascular resistance 
(peripheral vascular resistance) reflects the peculiar systemic hemodynamics in 
cirrhotic patients [29–32]. TPR (dynes s cm−5) was calculated using the following 
formula: TPR = mAP × 80/CO [30, 33]. 
In our institution, to evaluate the function of the right ventricle (RV), an acute volume 
challenge test (AVCT) was performed during catheter study before LDLT. Normal 
saline of 10 ml/kg body weight was injected for 6–7 min via cardiac catheter. 
We also evaluated the temporal changes in each of the parameters: (1) upon initial 
diagnosis of PAH (cardiac catheterization study); (2) after the induction of treatment 
(cardiac catheterization study); (3) during LDLT (via Swan-Ganz catheter after the 
induction of anesthesia); (4) after LDLT in the ICU (after weaning from respiratory 
ventilation); (5) up until discharge or the first cardiac investigation after discharge 
(catheterization study); and (6) the latest cardiac investigation after LDLT 
(catheterization study). 
Immunosuppression 
Immunosuppression after LDLT comprised tacrolimus and methylprednisolone. The 
trough level of tacrolimus was maintained at 8–15 ng/ml during the early 
postoperative period, based on the clinical findings in each case. Methylprednisolone 
was given intravenously (1 mg/kg) once daily from postoperative days (POD) 1–3 
followed by 0.5 mg/kg once daily for the next 3 days. On POD 7, 0.3 mg/kg of 
methylprednisolone was given intravenously. Steroids were switched to oral 
prednisolone 0.3 mg/kg once daily on POD 8, and this dose was reduced to 0.1 mg/kg 
4 weeks after LDLT. Thereafter, the immunosuppression was controlled according to 
each clinical course. 
Histopathological analysis of native livers and liver needle biopsy results 
Native livers were assessed macroscopically and microscopically by at least two 
experienced histopathologists. If necessary, liver needle biopsy (LNB) was performed 
after LDLT. Five of the six PAH patients underwent LNB. Liver tissues were fixed in 
neutral-buffered formalin, embedded in paraffin and sliced into sections (4 μ m thick). 
The histopathological findings were assessed after standard hematoxylin and eosin 
staining, and hepatic fibrosis was reconfirmed by Masson trichrome and reticulin 
staining. Liver fibrosis was scored using a five-grade scale (F0–F4) according to the 
METAVIR scoring system [34]: F0, no fibrosis; F1, portal fibrosis without septa; F2, 
portal fibrosis with rare septa; F3, numerous septa without cirrhosis; F4, cirrhosis. 
Statistical analysis 
Results were expressed as the median and the range. Survival rates were calculated 
using the Kaplan-Meier method, and the log-rank test was used for between-group 
comparisons. The differences between unpaired continuous or discontinuous variables 
between two groups were analyzed by Student’s t test. For individually, temporally 
and repeatedly measured data, the differences in changes over time between groups 
were analyzed by repeated measures ANOVA. Statistical calculations were performed 
using SPSS Software, version 17.0 (SPSS Inc., Chicago, IL, USA). A p value of <0.05 
was considered to be statistically significant. 
Results 
Profiles before LDLT 
All patients had a confirmed history of respiratory disturbances such as hypoxemia, lip 
cyanosis and puffing when breathing. The standard deviations in height and body 
weight were 0 (range 0.8–0.5) and −0.1 (range −0.9 to 0.3), respectively. Four of five 
recipients (aged <20 years) had a history of reduced growth. The United Network for 
Organ Sharing (UNOS) status was estimated to be III in five cases and IIB in one case. 
The median model for end-stage liver disease (MELD) or pediatric end-stage liver 
disease (PELD) score was 4.5 points (range 0–13 points). Grafts in five cases were 
from the father and in one case from the mother. Human leukocyte antigen typing 
indicated no barriers to LDLT. The ABO blood groups were identical in four cases, and 
compatible in two cases. The pre-transplant profiles are summarized in Table 1. 
Surgical treatments before LDLT 
Overall, 5/6 patients had undergone surgery before LDLT. All of the CBA cases had 
undergone Kasai’s operation. Two of these cases received additional surgery after 
Kasai’s operation: one for a distal spleno-renal shunt due to portal hypertension 
(case 1), and another underwent seven re-boring operations (case 3). One patient 
with AM type II underwent ligation of a porto-systemic shunt 4.2 years before LDLT 
(case 5). Surgery performed prior to LT is outlined in Table 1. 
Treatment for PAH prior to LDLT 
The interval from initial diagnosis of PAH to LDLT was 0.96 years (range 0.8–11.9 
years). Continuous intravenous prostaglandin I2 (PGI2) was given to all patients before 
LDLT, and oxygen was given in 5/6 cases. 
Catheterization studies before LDLT showed that 4/6 patients (cases 3–6) had a 
positive reaction to the loading tests and/or a negative response to the AVCT, though 
two patients showed low reactivity against the loading tests and a positive response 
to the AVCT (case 1 and 2). In case 2, PGI2 treatment was discontinued 8.8 years 
after LDLT owing to a catheter-related infection, and deteriorations in quality of life 
and activities of daily living. Thereafter, PAH worsened temporarily. In retrospect, we 
feel that PGI2 had a positive effect on reducing PAH in case 2. The period of PGI2 
treatment prior to LDLT ranged from 6 to 9 months. 
Currently, in our institution, we determine the time point after induction of anesthesia 
at which LDLT should be performed. The cutoff level for mPAP (measured via a 
Swan-Ganz catheter) is 35 mmHg. If mPAP is >35 mmHg, we postpone LDLT and 
continue to manage the PAH. LDLT is performed when the mPAP after anesthesia is 
controlled at ≤35 mmHg. Although LDLT was postponed in two cases in the present 
study (cases 3 and 4), these patients received LDLT after further treatment for PAH. 
The mPAP and PVR values at the time of LDLT were 34.0 mmHg (range 23–54 mmHg) 
and 244.4 dynes s cm−5 (range 81.8–281.7 dynes s cm−5), respectively. The treatments 
for PAH prior to LDLT are summarized in Table 2. 
 
Profiles during LDLT 
The median operation time was 628 min (range 484–931 min), and the median amount 
of intra-operative blood loss was 2965 ml (range 420–3,970 ml). Graft types were as 
follows: two extended lateral segment grafts, two left lobe grafts, one posterior 
segment graft and one right lobe graft without the middle hepatic vein. The median 
body weight was 26.0 kg (range 15.4–61.6 kg), and the median graft weight was 342.5 g 
(range 280–790 g). The median graft-to-recipient weight ratio (GRWR) was 1.30 g 
(range 0.95–2.24) (Table 1). A small-for-size graft is defined as a graft to GRWR <0.8 
or a ratio of graft weight against standard liver volume <40%, and these grafts result in 
a high mortality and morbidity [35, 36]. Our six cases in this study had appropriate 
graft size, though LDLT can not avoid inevitable insufficiency of allograft size. The 
median cold ischemic time was 73.5 min (range 26–346 min), and the median warm 
ischemic time was 30.5 min (range 22–61 min). The median anhepatic phase was 58.5 
min (range 42–75 min). Though a side clamp of the inferior vena cava was performed 
during LDLT, a total clamp could not be performed. Temporal portal-systemic shunt 
was made only in case 1, though we currently do not use temporal portal-systemic 
shunts. From 2006, an intentional control of portal venous pressure <15 mmHg was 
performed during adult LDLT in our institution. Retrospectively, portal venous 
pressure was monitored only in case 3. 
Cirrhotic findings at LT 
The Child-Pugh score was 6.5 points (range 5–10 points). Imaging studies prior to 
LDLT showed that 3/6 cases (cases 1, 2 and 4) had cirrhosis. The CO, CI and TPR 
values were 5.88 l/min (range 3.60–17.60 l/min), 5.49 l/min/m2 (range 3.33–17.40 
l/min/m2) and 942.9 dynes s cm−5 (range 327.3–1361.3 dynes s cm−5), respectively. 
Hepatic fibrosis in the native livers was assessed as follows: two at F3 and one each 
at F0, F1, F2 and F4 (Table 3). 
Liver cirrhosis was apparent in three cases (cases 1, 2 and 4); the other three cases 
(cases 3, 5 and 6) did not seem to have signs of advanced liver cirrhosis. Statistical 
differences were found between cirrhotic and non-cirrhotic patients with regard to 
the Child-Pugh score (p = 0.0023), TPR (p = 0.0164) and the F score (p = 0.0249). 
Although the CO and CI values were higher in cirrhotic recipients than in 
non-cirrhotic recipients (Table 3), these differences did not reach statistical 
significance. 
Clinical course and outcome after LDLT 
The length of hospital stay was 55.0 days (range 51–97 days), and the follow-up LNBs 
were F0 and F1. One patient died on POD 12. The follow-up term in the surviving 
patients was 3.6 years (range 1.8–9.9 years) (Table 4). The survival curves after LDLT 
showed no statistical differences in survival rates between LDLT recipients with or 
without PPHTN (p = 0.8114). The results of long-term blood gas analyses after LDLT 
in 4/6 patients are shown in Table 4. Case 4 showed no respiratory discomfort after 
LDLT, so blood gas analysis was not performed in this case. 
Catheter-related infections occurred in 5/6 cases (83.3%) during PGI2 therapy. In four 
cases (cases 3–6), PGI2 was successfully withdrawn after LDLT, and the patients 
were followed-up. In one case (case 2), PGI2 was stopped 8.8 years after LDLT 
without stable mPAP. The time of PGI2 withdrawal after LDLT was 1.9 years (range 
0.9–8.8 years) in the surviving five cases (Table 2). 
In one patient (case 1), PAH became worse after LDLT regardless of intensive care, 
causing cardiac failure and death. In case 2, PAH became worse 2 years after LDLT. A 
remnant from a spleno-renal shunt was detected, and we consider that this 
contributed to the increase in PAH. Splenectomy and ligation of the shunt were 
subsequently performed on POD 783. However, the resulting decrease in mPAP was 
not enough. Therefore, these two cases (cases 1 and 2) were considered to be 
PPHTN recipients with a poor clinical course and outcome after LDLT (Table 4). 
In case 4, surgical hemostasis was performed on POD 1 and 12 because of 
intraperitoneal bleeding after LDLT. In this case, a hemorrhagic tendency was 
observed. Acute cellular rejection (ACR), which was observed in four cases, was 
successfully treated by steroid pulse therapy (SPT). Drug-induced liver dysfunction 
was also successfully treated (Table 4). 
Changes of cardiac and Swan-Ganz catheter parameters before, during and 
after LDLT 
The changes in mPAP, CO, SVR and TPR before, during and after LDLT are shown in 
Fig. 1. 
The p values between cirrhotic and non-cirrhotic patients relating to changes in 
mPAP, CO, PVR and TPR were 0.1478, 0.0495, 0.4269 and 0.0030, respectively. The 
changes in CO and TPR in cirrhotic and non-cirrhotic recipients were significantly 
different (Table 5). The two patients (cases 1 and 2) with increased PAH after LDLT 
both had liver cirrhosis. The p values related to changes in mPAP, CO, PVR and TPR 
over time in recipients with or without a good clinical course were 0.0256, 0.7582, 
0.3767 and 0.3789, respectively. The difference in mPAP between patients with or 
without a good clinical course after LDLT was statistically different (Table 5). 
 
Discussion 
The cirrhotic hemodynamic state is characterized by high CO or CI values, a large 
blood volume (BV), a reduced or normal central BV, a low TPR, mild tachycardia and 
low or normal aortic pressure [30, 37–39]. In particular, TPR is considered to be the 
most reliable indicator of vascular alterations in cirrhotic patients [30–32]. The 
peculiar hemodynamics seen in cirrhosis are referred to as ‘hyperdynamic,’ and are 
indicated by a large BV, high CO and a low TPR [33, 40]. Previous studies clearly show 
that a systemic hemodynamic state persists in cirrhotic recipients after OLT 
regardless of the restoration of portal pressure [33, 37, 41, 42] and that optimal 
systemic hemodynamics are required for excellent outcomes after OLT [33, 40, 43]. 
Even subtle disorders in systemic hemodynamics during the early postoperative 
period after OLT may result in decreased splanchnic flow [33, 40], subsequently 
disrupting liver regeneration [43]. The two cases (cases 1 and 2) with persistently 
elevated PAH after LDLT both had liver cirrhosis. One patient died during the early 
postoperative period (case 1). Because the cirrhotic hyperdynamic state is one of 
several possible reasons for PAH in this case, postoperative management on the 
dry-side may be effective in controlling mPAP. However, maintenance of a 
hyperdynamic state during the perioperative period is important for excellent OLT 
results in cirrhotic patients because the collateral vessels do not disappear 
immediately, even after restoration of portal pressure [33, 40, 43]. Small BVs result in 
decreased portal flow and subsequent graft loss. Thus, the postoperative management 
of cirrhotic patients after OLT involves the dilemma of maintaining a low mPAP. 
The etiology of PPHTN is still unclear, although several mechanisms have been 
suggested. One hypothesis is that the cirrhotic hyperdynamic state itself causes mild 
increases in pulmonary arterial pressure and shear resistance in the pulmonary 
vessels. Another is that some vasoactive substances impact on the pulmonary 
vascular bed, as patients with portal hypertension show increased concentrations of 
vasoactive substances such as endothelin-1 (ET-1), angiotensin II, norepinephrine, 
vasopressin, nitric oxide (NO), leukotriene, endotoxin and serotonin [44–47]. These 
vasoactive substances, which are usually metabolized in the liver via the portal flow, 
are not defused in cirrhotic livers, or do not flow into the liver because of the 
formation of collateral vessels [45, 48, 49]. Subsequently, these substances flow 
directly into the right side of the heart. This pathway may explain PPHTN in patients 
with porto-systemic shunts. In one case (case 1), a distal spleno-renal shunt was 
performed to control the portal pressure. We do not recommend this type of surgical 
treatment for PPHTN patients because of the risk of PAH caused by vasoactive 
substances, as porto-systemic shunts may exacerbate PAH. 
We performed LDLT in two patients with AM (cases 5 and 6). Because of the 
mechanisms involved and the malignant potential of this condition [28], OLT may 
become the definitive treatment for PPHTN patients with porto-systemic shunts. We 
suggest that PPHTN patients with PAH due to porto-systemic shunts are good 
candidates for LDLT, although ligation of the porto-systemic shunts should be the 
initial treatment for patients with AM type II. 
Several therapies for PAH have been documented. Because of advances in diagnosis 
and treatment over the last 2 decades, the median survival rates for PPHTN patients 
with PAH have improved from 68 to 81.1% at 1 year, to 48–61.1% at 3 years, and 
34–57.9% at 5 years [50]. PPHTN requires the correct treatment. Many agents, such 
as oxygen, nitric oxide, phosphodiesterase 5 inhibitors and ET-1 receptor antagonists 
are effective for the treatment of PPHTN patients with PAH [5, 51–53]. However, 
some agents have side effects, such as increasing the effects of immunosuppressant 
drugs, hepatocyte toxicity and enhancement of the cirrhotic hyperdynamic state [23, 
54, 55]. Thus, some agents cannot be used after OLT. After the introduction of 
epoprostenol (a synthetic analogue of prostacyclin, PGI2), the outcome for PPHTN 
patients with PAH improved [5, 54]. Currently, PGI2 is considered a key drug for the 
control of PAH [20, 21]. However, PGI2 also has problems, including central line 
placement, drug preparation/handling, intensive patient education and the inhibition of 
platelet aggregation [54]. Hemorrhagic tendency is one problem during the early 
postoperative period, and 1/6 cases (case 4) required additional surgery after LDLT 
because of inhibited platelet coagulation caused by continuous PGI2 administration. 
However, PGI2 is only active for a short time and is chemically unstable [although the 
compound has adequate stability for 24 h in carbonate buffer (pH 10.0) at 0°C]. Also, 
a mobile device is required for continuous infusion, and a central venous catheter is 
needed to avoid painful vein irritation caused by peripheral administration [56]. The 
incidence of catheter-related sepsis has been reported as 0.1–0.6 cases per 
patient-year [56, 57]. Immunosuppression after LDLT carries a risk of infection (the 
rate of catheter-related infections in our patients was high). Thus, quality of life and 
activities of daily living may be disturbed. Indeed, we had to discontinue PGI2 
treatment in one case for these very reasons (case 2). However, the effective control 
of moderate/severe PPHTN prior to OLT is associated with excellent outcomes [19], 
and we speculate that PGI2 still plays an important role before, during and after LDLT. 
PGI2 therapy was successfully withdrawn in four cases after LDLT. We found no 
significant differences in PVR between PPHTN patients, regardless of clinical course. 
However, unstable mPAP appeared to be associated with the clinical course. One 
possible explanation is that PGI2 affected vasoconstriction and pulmonary vascular 
remodeling, even in PPHTN patients with unsatisfactory reductions in mPAP. In one 
case, PAH worsened 2 years after LDLT (case 2), and a remnant from a spleno-renal 
shunt was detected. At that time, we considered that this shunt may have caused the 
increase in PAH. Therefore, ligation of the shunt and splenectomy were performed. 
However, the decrease in mPAP was still insufficient. One possible explanation is that 
organic consolidation within the pulmonary vessels had already occurred during the 
course of the disease. In this case, no signs of cardiac failure were detected 9.9 years 
after LDLT, though a temporal increase in PAH was observed after withdrawal of PGI2. 
Previous studies show that only 29% of untreated PPHTN patients survive after OLT 
[10] and that patients with moderate/severe PPHTN (mPAP >35 mmHg and PVR 
>250 mmHg) have a >90% risk of death after OLT [13]. Effective pharmacological 
control of moderate/severe PPHTN prior to OLT is associated with excellent survival 
rates [19]. 
Our results showed that two recipients of LDLT (cases 1 and 2) had poor a response 
to treatment before LDLT, and their mPAP showed different courses after LDLT 
compared with the other four patients. The clinical course in these two cases were 
retrospectively consistent with the currently documented criteria prior to OLT [13, 16, 
17] and illustrate the importance of intensive preoperative control of PAH for 
successful OLT [19]. The flowchart currently used in our institutional guidelines for 
LDLT in PPHTN patients is shown in Table 6. PGI2 therapy was introduced when 
mPAP was >35 mmHg. Though we want to shorten the waiting times for LDLT, this 
therapy may be continued for 6–9 months prior to LDLT if necessary. Retrospectively, 
three cases (cases 1–3) did not fulfill the criteria set out in previous studies (mPAP 
>35 mmHg and PVR >250 mmHg) [13, 16, 17], and two cases (cases 1 and 2) did not 
conform to our own institutional guidelines. In PPHTN patients, the RV is well 
designed for volume transmission, but does not have the muscle power to deal with 
the increased work caused by an increased afterload unless the load develops very 
gradually to allow hypertrophy of the RV muscle. In the presence of decreased RV 
contractility, as seen in cases of cirrhotic cardiomyopathy, or dilatation from volume 
overload or increased afterload, the RV is even more sensitive to increases in work 
load and may become dysfunctional and fail. Right ventricular failure is commonly 
caused by acute increases in PVR. Once failure occurs, cardiac function declines at 
an accelerated pace. During OLT, temporal clamping of the inferior vena cava and 
hepatic vein, and the portal reflow after the anhepatic phase cause acute volume 
overload to the right side of the heart, and this stress may result in right heart failure. 
After the restoration of portal reflow, vasoactive substances may stimulate the 
pulmonary artery and subsequently cause the paroxysms associated with pulmonary 
hypertension. Our institution currently uses AVCT before LDLT to confirm RV 
function against acutely increased preloading. When mPAP is <40 mmHg, we perform 
AVCT. LDLT is considered if PAH is controllable and if cardiac function can be 
maintained during the clinical course. A decision is also based on the findings from 
catheter examinations and the level of brain natriuretic peptides. In our institution, 
cardiopulmonary variables during LDLT are checked using a Swan-Ganz catheter, and 
LDLT may be postponed and internal treatments reconsidered if mPAP is >35 mmHg 
after the induction of general anesthesia. This strategy seems to work well, even 
though LDLT was postponed in two cases. We suggest that a hasty decision to 
perform LDLT will lead to worse results in PPHTN patients and that thoughtful 
decision making regarding the advantages of LDLT may be the key to successful 
LDLT in PPHTN patients. This is because OLT is based on the advantages of LDLT, 
as the timing of LDLT is more flexible than that of DDLT. 
Previous researchers documented that the mPAP value should be decreased as <35 
mmHg, preoperatively [58, 59]. General anesthesia involves invasive factors and may 
affect mPAP values after the induction. Then, we agreed that preoperative mPAP <35 
mmHg is an ideal. Actually, we still have some concerns about registering patients 
with 35–40 mmHg mPAP as LDLT recipients. Preoperative reactivity for 
pharmacological control of moderate/severe PPHTN is a key for excellent survival 
rates [19]. Though case 4 preoperatively showed marginal mPAP (mPAP 35 mmHg at 
LDLT) in comparison with previous documents and actually received a postponement 
of LDLT, this patient had well-kept RV function and a favorable course after 
treatment induction. Case 6 (mPAP 35 mmHg at LDLT) survived for 9.9 years after 
LDLT. Our cutoff level for LDLT registration (mPAP <40 mmHg) may seem higher than 
that in other institutions. The timing of LDLT is more flexible, and paradoxically the 
criteria of mPAP ≤35 mmHg after anesthesia induction seemed to work as a final 
check point before LDLT. Although we still do not have enough experience, we 
currently speculate that some patients with mPAP of 35–40 mmHg may have potential 
as LDLT candidates. 
Treatment of PPHTN should be considered because non-treated patients have 
terrible outcomes. However, effective PPHTN treatment in candidates for OLT still 
requires well-designed prospective studies to establish formal guidelines [18]. Overall, 
we believe that, in some cases, PPHTN patients with PAH are potentially curable and 
that LDLT can achieve good results. PPHTN patients with well-controlled PAH, or 
secondary PAH due to porto-systemic shunts, may be appropriate candidates for 
LDLT after thoughtful consideration of the relevant factors, including the clinical 
course, results of catheterization studies and Swan-Ganz monitoring, the response to 
therapeutic agents and the findings of imaging studies. Close follow-up after LDLT are 
also crucial to establish good results in PPHTN patients. 
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+ – III 13 Identical 1.28 
2 LDLT 6.5 CBA 
Kasai’s 
operation 
+ + III 2 Identical 1.22 






+ N/A III 11 Identical 1.29 
4 LDLT 9.2 CBA 
Kasai’s 
operation 
+ + IIB 3 Identical 0.95 






+ + III 0 Compatible 1.57 
6 LDLT 5.0 
AM type 
Ib 
– + + III 6 Compatible 2.24 
AM Abernethy malformation, CBA congenital biliary atresia, GRWR graft-to-recipient 
weight ratio, LDLT living-donor liver transplantation, MELD model for end-stage liver 
disease, N/A not applicable, OLT orthotopic liver transplantation, PAH pulmonary 
arterial hypertension, PELD pediatric end-stage liver disease, PPHTN 
porto-pulmonary hypertension, UNOS United Network for Organ Sharing 
aRespiratory symptoms included hypoxemia, lip cyanosis and puffing when breathing 



































































+ 9 – 23 222.2 + + (0.9) 
AVCT acute volume challenge test, LDLT living-donor liver transplantation, mPAP 
mean pulmonary arterial pressure, PAH pulmonary arterial hypertension, PGI2 
prostaglandin I2, PPHTN hypertension, PVR pulmonary vascular resistance 
aTime from diagnosis to LDLT 
bMedications at the time of LDLT 





















1 8 + + 7.00 4.19 765.7 F3 
2 9 + + 7.10 8.88 754.9 F3 
3 5 – – 4.50 3.33 1120.0 F2 
4 10 + + 17.60 17.40 327.3 F4 
5 5 – – 4.76 5.60 1361.3 F1 
6 5 – – 3.60 5.37 1288.9 F0 
CI cardiac index, CO cardiac output, LDLT living-donor liver transplantation, TPR 
total peripheral resistance 






















Episodes during LDLT and clinical course and outcomes after LDLT 














oversystemic PAH, cardiac 
failure 




ACR (SPT), sepsis confounded 
PAH 2 years after LDLT. The 
remnant of spleno-renal shunt 
(splenectomy and the ligation 
of shunt at POD 783) 
97 69.2 F1 
Alive (9.9 
years) 






(surgical hemostasis at PODs 1 
and 12), ACR (SPT) 




Drug-induced liver dysfunction 
(the cessation of suspected 
drugs) 
58 78.3 F0 
Alive (3.6 
years) 
6 ACR (SPT) 55 100.5 F0 
Alive (1.8 
years) 
ACR acute cellular rejection, LDLT living-donor liver transplantation, LNB liver needle 
biopsy, SPT steroid pulse therapy, PAH pulmonary arterial hypertension, POD 
postoperative day 
aLong-term blood gas analysis of PaO2 levels after LDLT 
bHistopathological assessment in LNBs after LDLT using the METAVIR score. The 




 Fig. 1 
Changes in mPAP, CO, PVR and TPR before, during and after LDLT. The mPAP, CO, 
PVR and TPR values are shown at each time point after LDLT. Filled circles, triangles, 
open circles and diamonds represent cases 1–4. Squares represent cases 5 and 6 
combined. Red lines represent cirrhotic recipients (cases 1, 2 and 4) and blue lines 
represent non-cirrhotic recipients (cases 3, 5 and 6). The changes in CO and TPR 
between cirrhotic and non-cirrhotic recipients over time were significantly different. 
Dotted lines represent recipients with a poor clinical course (cases 1 and 2), and solid 
lines represent recipients with a good clinical course (cases 3–6) after LDLT. The 
changes in mPAP over time between recipients with poor or good clinical courses 









Statistical differences in the changes over time between groups for each variable 
before, during and after LDLT 
 
Statistical differences between 
cirrhotic and non-cirrhotic patients 
(cases 1, 2 and 4 vs. cases 3, 5 and 
6)† 
Statistical differences between 
recipients with or without good clinical 
courses after LDLT (cases 1 and 2 vs. 
cases 3–6)† 
mPAP 0.1478 0.0256†† 
CO 0.0495†† 0.7582 
PVR 0.4269 0.3767 
TPR 0.0030†† 0.3789 
CO cardiac output, LDLT living-donor liver transplantation, mPAP mean pulmonary 
arterial pressure, PVR pulmonary vascular resistance, TPR total peripheral resistance 
†The statistical differences between groups in the changes over time of each variable 
were analyzed by repeated measures ANOVA 





















Flowchart of pre-transplant treatments for PPHTN patients with PAH 
 
AVCT acute volume challenge test, BNP brain natriuretic peptide, CVP central 
venous pressure, LDLT living-donor liver transplantation, mPAP mean pulmonary 
arterial pressure, PAH pulmonary arterial hypertension, PCWP pulmonary capillary 
wedge pressure, PGI2 prostaglandin I2, PPHTN porto-pulmonary hypertension, RVEDP 
right ventricle end diastolic pressures 
 
 
